Buy Rating on Briumvi Driven by Strong Commercial Momentum, 2026 Growth Outlook, and Underappreciated Autoimmune Pipeline Optionality

H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on TGTX stock, giving a Buy rating today.

Emily Bodnar’s rating is based on the company’s strong commercial momentum and aligned financial outlook for Briumvi. Preliminary 2025 revenue slightly exceeded her projections, with particularly robust fourth-quarter sales reinforcing confidence in execution. Management’s 2026 revenue guidance, while somewhat more cautious than her own model, still implies healthy year-over-year growth, and the company has a track record of surpassing its forecasts. Planned operating spending and one-time launch-related costs indicate improving operating leverage as the franchise scales.

Emily Bodnar has given his Buy rating due to a combination of factors that extend beyond near-term sales. She anticipates meaningful clinical catalysts in 2026, including pivotal data readouts for both consolidated IV dosing and the self-administered subcutaneous formulation of ublituximab, which could meaningfully broaden Briumvi’s market share against competing anti-CD20 therapies. Additional planned studies for Briumvi and the azer-cel CAR-T program in multiple autoimmune indications create a pipeline-within-a-product dynamic that is not fully reflected in current valuation. The company’s intention to selectively expand its sales and marketing footprint, while leveraging existing high coverage of target prescribers, further supports the sustainability of growth and underpins her constructive stance on the stock.

Bodnar covers the Healthcare sector, focusing on stocks such as Agios Pharma, Geron, and Olema Pharmaceuticals. According to TipRanks, Bodnar has an average return of 12.4% and a 34.00% success rate on recommended stocks.

In another report released today, TipRanks – Google also upgraded the stock to a Buy with a $33.00 price target.